| Project/Area Number |
24590225
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Mukogawa Women's University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YAMAMORI Motohiro 武庫川女子大学, 薬学部, 講師 (10444613)
FUJITA Megumi 武庫川女子大学, 薬学部, 講師 (50509966)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 膵臓がん / PPARγ / アポトーシス |
|---|
| Outline of Final Research Achievements |
Effect of troglitazone, a PPARγ agonist, on human pancreatic cancer cell lines, troglitazone exhibited inhibitory activity on cell proliferation in concentration dependent manner. Also, it was suggested that PPARγ did not involved in the activity. Although no important pathway was revealed in Panc-1 cells, the JNK pathway was involved in the activity in MIA Paca-2 cells. In addition, effect of oral administration of troglitazone on tumor progression in tumor-bearing mouse using MIA Paca-2 cells was investigated. Although any significant difference was not observed, tumor volume and weight tended to decrease, suggesting the possibility of troglitazone having anti-tumor effect in in vivo.
|
